A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
VB-111 is an experimental gene therapy being tested for use in recurrent Glioblastoma. As I mentioned in the previous article, the results for the phase 1/2 trial came out on the same day as the results of the phase 3 trial. I do not think I ever saw that happen before. The Phase 1/2 trial came out very good however, this failed to show any improvement of VB-111 plus Avastin randomized against Avastin alone in recurrent GBM. If they had the results of the phase1/2 trial before they designed this phase 3 trial, they might have designed it differently as the phase 1/2 trial showed that using VB-111 alone until recurrence, then continuing vb-111 and adding avastin did much better than starting with VB-111 and Avastin at the same time. This shows that adding combinations doesn't always improve the outcome. Everything needs to be tested and timing is very important.
I am still a fan of VB-111 but think it needs more work to find the optimal way to use it.
Posted on: 12/25/2019
Click HERE to return to brain tumor news headlines